2 Stocks That Could Turn $1,000 Into $2,500 in 5 Years
It will take a lot, but this goal isn't out of reach for these stocks.
This Stock Has Quadrupled in 5 Years. Can It Do It Again?
Have investors already missed the boat with this stock?
2 Soaring Stocks With More Upside Potential
Are these mid-cap stocks giants in the making?
What Will AbbVie Buy Next?
Two mid-cap drugmakers stand out as logical targets for AbbVie.
Up 48% in 2023, Is This Biotech Stock a Buy?
How much longer can this biotech's run last?
Regulatory momentum, bullish Wall Street analysts and favorable technicals all suggest Krystal Biotech, Inc. may be a gem.
Why Shares of Krystal Biotech Are Rising Monday
The company is moving quickly to market its newly approved therapy.
2 Risky Stocks That Could Soar in 2023
These "exciting" companies aren't for everyone.
2 Growth Stocks That Could Double in the Next Year
Just don't be too quick to press the buy button.
Krystal Biotech Announces FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical Trial
KB407 is an investigational, redosable gene therapy candidate designed to treat all patients with cystic fibrosis regardless of the underlying genetic...